Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synchrotope TA2M · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Synchrotope TA2M, 800 micrograms | EXPERIMENTAL | Tyrosinase peptides, 800 micrograms |
| Synchrotope TA2M, 200 micrograms | EXPERIMENTAL | Tyrosinase peptides, 200 micrograms |
| Synchrotope TA2M, 400 micrograms | EXPERIMENTAL | Tyrosinase peptides, 400 micrograms |
| Name | Type | Description |
|---|---|---|
| Synchrotope TA2M | BIOLOGICAL | Cancer Vaccine, Immunotherapy |
INCLUSION CRITERIA - Patient must meet the following during the screening and baseline visits: 1. The patients or their legally acceptable representative must give signed informed consent for participation in the study before any study procedure is performed. 2. Patients must be 18 years of age or ...
Top 20 of 51 competitors
Synchrotope TA2M is an investigational monoclonal antibody being developed for the treatment of melanoma, a type of skin cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
Synchrotope TA2M is a monoclonal antibody, a type of therapy designed to bind to specific proteins involved in disease. However, its specific molecular target has not been disclosed in available information, so the exact mechanism of action is not publicly detailed.
Synchrotope TA2M is being developed by MannKind Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol MNKD. The company is responsible for advancing this investigational therapy through clinical trials.
Synchrotope TA2M is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
Synchrotope TA2M has been studied in one clinical trial, identified as NCT00023647, titled "Vaccine Therapy in Treating Patients With Stage IV Melanoma." This Phase 1 study was completed in the United States and enrolled 26 participants aged 18 years and older.
Synchrotope TA2M is a monoclonal antibody, not a vaccine. Although the clinical trial NCT00023647 was titled "Vaccine Therapy," the drug itself is classified as a monoclonal antibody, which is a different type of therapeutic agent from a vaccine.